# Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

> **NCT00688415** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 33 (actual)

## Conditions studied

- Advanced Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** VTX-2337

## Key facts

- **NCT ID:** NCT00688415
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-07
- **Primary completion:** 2010-08
- **Final completion:** 2010-11
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00688415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00688415, "Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00688415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*